Monopar Therapeutics Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Rolling submissions get reviewed faster, potentially bringing a new treatment to patients sooner.
This designation offers tax credits and market exclusivity, making the drug more valuable if approved.
Better results in late-stage testing increase the chance the FDA will approve the drug.
Board elections and pay approval show shareholders support company leadership's decisions.
Earlier-stage proof that the drug works helps build the case for final FDA approval.
Positive trial results reduce risk that the drug won't work, supporting investor confidence.
10-Q reports let investors see how much money the company has and how it's spending it.
Stocky reads Monopar Therapeutics Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Monopar Therapeutics Inc.'s most recent tracked filing was a 8-K on 22 Jul 2026: Started rolling FDA submission for Wilson disease drug ALXN1840.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.